BEONE MEDICINES

Forecast & Rating16 analysts currently cover BEONE MEDICINES, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is HK$256.58, about 30.8% upside from the current price of HK$196.10. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 64.0% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study BEONE MEDICINES closely still see room for the stock to rise. Data as of Jul 25, 2026; for reference only and not investment advice.